ANI Pharmaceuticals Conference Call Announcement
ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) has announced that it will be revealing its financial results for the second quarter of 2025. This is a significant event for the company as it aims to provide insights into its performance and future outlook. The results will be released before the market opens on a Friday.
Details of the Conference Call
Following the financial results release, key executives will be participating in a conference call to discuss the findings with stakeholders and interested parties. The call will feature Nikhil Lalwani, the President and CEO, along with Stephen P. Carey, the Senior VP of Finance and CFO, Chris Mutz, the Head of Rare Disease, and Dr. Mary Pao, the Chief Medical Officer.
Call Timing and Access Information
The conference will take place at 8:30 a.m. ET, providing an excellent opportunity for investors and analysts to engage directly with the company’s leadership. Participants in the U.S. can join the conference call toll-free at 800-343-4136, using the conference ID 5034065.
Availability of Conference Call Replay
For those who cannot join live, a replay of the conference call will be accessible. It will be available just a couple of hours after the call concludes and can be listened to for the following two weeks. To access the replay, individuals can dial 800-839-6803 and enter the same access code, 5034065.
About ANI Pharmaceuticals, Inc.
ANI Pharmaceuticals, Inc. is a versatile biopharmaceutical company dedicated to enhancing patient care through the development and commercialization of high-quality therapeutics. Their mission, "Serving Patients, Improving Lives," reflects their commitment to providing innovative solutions in various therapeutic areas. This includes their Rare Disease segment, which focuses on ophthalmology, rheumatology, nephrology, neurology, and pulmonology, as well as their Generics and Brands businesses.
Continuous Innovation and Growth
ANI's strategy revolves around sustainable growth by investing in research and development while ensuring operational excellence through U.S.-based manufacturing. This holistic approach enables them to deliver a broad range of therapeutics effectively.
Contact Information for Investors
For inquiries, interested parties can reach out to Lisa M. Wilson at In-Site Communications, Inc. She is available at 212-452-2793. Those wishing to communicate via email can contact her at: lwilson@insitecony.com.
Frequently Asked Questions
What is ANI Pharmaceuticals' track record in the biopharmaceutical industry?
ANI Pharmaceuticals has a solid history of developing high-quality treatments across several therapeutic areas, known for its commitment to patient welfare.
How can I participate in the ANI Pharmaceuticals conference call?
Investors can join the call toll-free at 800-343-4136, using the conference ID 5034065 on the scheduled date and time.
Where can I find more information about ANI Pharmaceuticals?
More information can be found directly on the company’s website or by reaching out to their investor relations team.
Will there be a replay of the conference call?
Yes, a replay will be available shortly after the call ends and can be accessed for two weeks afterwards.
What are ANI Pharmaceuticals' focus areas for growth?
ANI is focusing on its Rare Disease segment, generics, and branded products, along with continued innovation in drug development.
